Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pulmozyme Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %
The expansion observed during the historical period is explainable by the well-documented effectiveness of treatments for alpha-1 antitrypsin deficiency, reinforced endorsement from pulmonology clinical guidelines, the consistent supply of plasma-derived protein therapies, prescribing habits among specialists, and better overall results in managing the disease.
The expansion of this market during the forecast period is driven by a larger implementation of genetic screening initiatives, a heavier disease burden from COPD, broader offerings in specialized respiratory care, better patient compliance, and the development of plasma collection facilities. Key developments expected to shape the forecast period include a growing reliance on augmentation therapy, heightened emphasis on halting COPD deterioration, extended utilization of plasma protein replacement over the long term, administration within hospitals and dedicated specialty clinics, and increasing public recognition of genetic lung conditions.
Download A Free Sample Report For Comprehensive Market Insights:
Pulmozyme Market Industry Drivers: What Is Driving Revenue Growth?
The anticipated increase in respiratory disorders is set to drive the pulmozyme market forward. These disorders, which affect the lungs and airways and impede breathing and oxygen exchange, encompass conditions like asthma, COPD, and pneumonia. Factors such as rising air pollution, smoking, occupational hazards, climate change, and a greater prevalence of allergens and infectious diseases are fueling this increase. Pulmozyme, also known as dornase alfa, is employed to treat respiratory issues like cystic fibrosis by breaking down thick mucus in the lungs, enhancing airflow and lowering infection risk. For example, a June 2024 report from the Australian Institute of Health and Welfare, an Australian health and welfare agency, revealed that about 8.5 million people in Australia, or 34% of the population, were estimated to have chronic respiratory conditions. This includes an estimated 2.8 million people, or 11% of the population, living with asthma, and 638,000 people, or 2.5% of the population, living with chronic obstructive pulmonary disease (COPD). Consequently, the growing prevalence of respiratory disorders is fueling the pulmozyme market.
A growing number of lung transplants is expected to boost the expansion of the pulmozyme market in the coming period. A lung transplant involves surgically replacing a diseased or failing lung with a healthy donor lung to address severe respiratory failure or chronic lung diseases. This increase stems from a higher incidence of chronic respiratory conditions like cystic fibrosis and COPD, along with improved surgical methods and enhanced post-transplant care that boost survival rates. Pulmozyme, a recombinant human DNase enzyme, aids lung transplant recipients by breaking down thick, sticky mucus in their airways, thereby lowering infection risks and improving lung function. This helps them breathe more easily and maintain respiratory health after the transplant. For instance, in August 2023, the National Health Service (NHS), a UK-based healthcare system, reported that the total number of UK citizens with active lung and heart-lung transplants rose from 267 in 2022 to 302 in 2023. Thus, the rising number of lung transplants is propelling the pulmozyme market.
Pulmozyme Market Segment Analysis Highlighting Growth Areas
The pulmozyme market covered in this report is segmented –
1) By Indication: Cystic Fibrosis, Respiratory Tract Infections
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By End User: Hospitals And Clinics, Homecare Settings
Pulmozyme Market Growth Trends: What Is Influencing The Future Outlook?
Major industry players in the cystic fibrosis treatment device market are prioritizing the development of advanced technologies, with particular emphasis on vibrating mesh nebulizers, to improve medication delivery, boost patient adherence to treatment, and enhance overall quality of life. Vibrating mesh nebulizers employ a fine mesh to produce a steady stream of aerosol, facilitating more precise and efficient lung deposition of medications like Pulmozyme. In a notable example from March 2024, HCmed, a medical technology firm based in Taiwan, secured FDA clearance for its Pulmogine Vibrating Mesh Nebulizer when used with Pulmozyme, positioning it as just the fifth FDA-approved mesh nebulizer compatible with that particular therapy. This regulatory milestone highlights the market’s strong emphasis on innovative delivery systems that maximize therapeutic effectiveness and patient outcomes.
Pulmozyme Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the pulmozyme market are Roche Holding AG
Access The Complete Pulmozyme Market Report:
Pulmozyme Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the pulmozyme market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmozyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model